Shares of Humacyte Inc. (HUMA) are down over 70% from their 52-week high of $9.97, recorded last May, to trade around $2.
The company markets Symvess, a first-of-its-kind human-derived biologic vessel, designed for adults who need urgent surgery to restore blood flow to a damaged limb, especially when using the patient's own vein is not feasible. Approved by the FDA for treatment of extremity vascular trauma in December 2024, Symvess, an acellular tissue-engineered vessel, was commercially launched in the U.S. in late February 2025. Symvess generated $147 thousand in revenue related to the initial U.S. commercial launch in the first quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.